Inventor
JADHAV VASANT R
US21 patents
⚠️ This page may combine multiple inventors who share the name “JADHAV VASANT R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
13 patentsUS11286486B2Mar 29, 2022
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC8 citations85
US11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US10683501B2Jun 16, 2020
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC8 citations83
US11492623B2Nov 8, 2022
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US12049628B2Jul 30, 2024
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC1 citations72
US11725209B2Aug 15, 2023
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations72
US10829763B2Nov 10, 2020
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US12275938B2Apr 15, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12247203B2Mar 11, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12173289B2Dec 24, 2024
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11725207B2Aug 15, 2023
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US10933081B2Mar 2, 2021
Myostatin iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
SIRNA THERAPEUTICS INC
7 patentsUS10689648B2Jun 23, 2020
Short interfering nucleic acid (siNA) compositions
SIRNA THERAPEUTICS INC5 citations81
US11530407B2Dec 20, 2022
Short interfering nucleic acid (siNA) compositions
SIRNA THERAPEUTICS INC1 citations70
US10729787B2Aug 4, 2020
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
SIRNA THERAPEUTICS INC2 citations69
US12486503B2Dec 2, 2025
Short interfering nucleic acid (siNA) compositions
SIRNA THERAPEUTICS INC0 citations59
US11529428B2Dec 20, 2022
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
SIRNA THERAPEUTICS INC0 citations59
US10508277B2Dec 17, 2019
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
SIRNA THERAPEUTICS INC0 citations41
US9994853B2Jun 12, 2018
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
SIRNA THERAPEUTICS INC0 citations41